PCOS renamed PMOS in major global move to better reflect women's health condition

Over 50 patient and professional organisations, including the Endocrine Society, have joined forces in a global effort to rename polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS). The decision marks a significant shift in how the condition is understood and addressed, aiming to better capture its multifaceted nature and impact on women’s health. The renaming initiative, spearheaded by Professor Helena Teede of Monash University’s Monash Centre for Health Research & Implementation, along with other leading experts, followed extensive research and consultations. The new name, PMOS, reflects the hormonal imbalances and metabolic issues linked to the condition, which affect weight management, mental well-being, skin health, and reproductive function. According to Teede, the previous name was scientifically inaccurate, as it implied an increase in abnormal ovarian cysts, which is not supported by current evidence. The transition to PMOS will take place over three years, during which a global education and awareness campaign will support healthcare professionals, researchers, governments, and patients. Full adoption is anticipated with the 2028 update of international guidelines. This initiative represents the largest effort ever undertaken to rename a medical condition, according to Teede, who highlighted the importance of aligning the name with accurate science, effective communication, and cultural sensitivity. A key aspect of the renaming process was ensuring the new name avoided stigmatizing language and respected diverse cultural contexts. Professor Terhi Piltonen, president of the International Androgen Excess and Polycystic Ovary Syndrome Society (AE-PCOS Society), emphasized that the name had to be both scientifically sound and culturally appropriate. She noted that certain reproductive-related terms could carry negative connotations in specific regions, potentially harming women’s health outcomes. The initiative involved more than 56 patient and professional groups, over 22,000 survey responses, and numerous international workshops featuring patients and multidisciplinary healthcare professionals. These efforts helped shape the new name, which integrates the metabolic and hormonal dimensions of the condition while avoiding outdated terminology. Researchers participating in the project confirmed that there is no increased prevalence of abnormal ovarian cysts associated with the condition, further supporting the need for a revised designation. Rachel Morman, chair of Verity (PCOS UK), praised the new name for its clarity and inclusivity. She stated that the previous label failed to adequately represent the condition’s broader implications. “It is fantastic that the new name now leads with hormones and recognises the metabolic dimension of the condition,” she said. Morman believes the change will foster greater public understanding and encourage the recognition of PMOS as a complex, chronic health issue rather than a disorder primarily defined by ovarian cysts. Lorna Berry, an Australian patient advocate living with the condition, expressed hope that the new name will lead to improved diagnosis and treatment for future generations. She participated in the renaming process and believes the updated terminology can enhance both personal experiences and systemic care. “This change has the potential to make a real difference in how women perceive and manage their health,” she said. As the transition to PMOS begins, stakeholders anticipate a gradual but impactful shift in clinical practice, educational materials, and public discourse. With continued collaboration among scientists, clinicians, and advocacy groups, the goal is to ensure that the new name not only reflects current scientific knowledge but also supports meaningful improvements in women’s health care worldwide.